Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors.Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35...
Saved in:
Main Authors: | A. A. Semenova, P. A. Zeynalova, M. S. Nikitina, M. I. Akhmedov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2019-01-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/320 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01) -
Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01) -
The Benefit of Brentuximab Vedotin and Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Retrospective Study
by: Diana-Marina FORTOES, et al.
Published: (2025-06-01) -
PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS
by: A. S. Kolbin, et al.
Published: (2017-05-01) -
SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)